Condition
Retroperitoneal Fibrosis
Total Trials
7
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Recruiting2
Completed2
Unknown2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT04047576Phase 2RecruitingPrimary
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
NCT06741423Active Not Recruiting
Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics
NCT06065852Recruiting
National Registry of Rare Kidney Diseases
NCT02705638Phase 1Completed
Treatment of IgG4-Related Disease With Revlimid and Rituximab
NCT01584388Phase 1CompletedPrimary
Rituximab in IgG4-RD: A Phase 1-2 Trial
NCT03133949Unknown
Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria
NCT00440349Phase 2UnknownPrimary
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
Showing all 7 trials